Skip to search formSkip to main contentSkip to account menu

EAPB0503

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Quinoxalines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy of the Imiqualine analog EAPB0503 against Cutaneous Leishmaniasis : A promising new treatment paradigm
Cutaneous Leishmaniasis (CL) is a parasitic infection classified by the WHO as one of the most uncontrolled spreading neglected… 
2016
2016
Effect of Imiquimod and derivatives compounds EAPB0203 and EAPB0503 on Leukemia/lymphoma models
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone… 
2014
2014
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry.
2010
2010
Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas
For several years, our group has been developing quinoxalinic compounds. Two of them, N-methyl-1-(2-phenethyl)imidazo[1,2-a… 
2009
2009
Etude Préclinique de Nouveaux Dérivés Imidazoquinoxaliniques, EAPB0203 et EAPB0503, Actifs sur les Mélanomes
Parmi les cancers de la peau, les melanomes sont ceux qui entrainent le plus de deces. Actuellement l’arsenal therapeutique… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)